Fosrenol

Fosrenol is a brand name of lanthanum carbonate, approved by the FDA in the following formulation(s):

FOSRENOL (lanthanum carbonate - tablet, chewable; oral)

• 
  Manufacturer: SHIRE
  
  Approval date: October 26, 2004
  
  Strength(s): EQ 500MG BASE
  


• 
  Manufacturer: SHIRE
  
  Approval date: November 23, 2005
  
  Strength(s): EQ 1GM BASE ^[RLD], EQ 750MG BASE
  

Has a generic version of Fosrenol been approved?

No. There is currently no therapeutically equivalent version of Fosrenol available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Fosrenol. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Pharmaceutical composition containing selected lanthanum carbonate hydrates
  Patent 5,968,976
  Issued: October 19, 1999
  Inventor(s): Murrer; Barry A & Powell; Nigel A
  Assignee(s): AnorMed Inc.
  Selected lanthanum carbonate hydrates may be administered into the gastrointestinal tract, to treat hyperphosphataemia in patients with renal failure.
  
  Patent expiration dates:
  
  
  • October 26, 2018
    
    ✓ 
    Patent use: REDUCTION OF SERUM PHOSPHATE
    ✓ 
    Drug product
  
  



• 
  Stabilized lanthanum carbonate compositions
  Patent 7,381,428
  Issued: June 3, 2008
  Inventor(s): Ferdinando; Josephine Christine & Davies; Peter Neil
  Assignee(s): Shire International Licensing B.V.
  Stabilized lanthanum carbonate compositions containing a monosaccharide or disaccharide stabilizing agent are disclosed. Subjects having hyperphosphatemia can be treated by administering a pharmaceutical composition containing a therapeutically effective amount of the stabilized lanthanum carbonate formulation.
  
  Patent expiration dates:
  
  
  • August 26, 2024
    
    ✓ 
    Patent use: REDUCTION OF SERUM PHOSPHATE IN PATIENTS WITH END STAGE RENAL DISEASE
  
  



• 
  Pharmaceutical formulation comprising lanthanum compounds
  Patent 7,465,465
  Issued: December 16, 2008
  Inventor(s): Haslam; Robert Paul & Trespidi; Laura Anna & Ferdinando; Josephine Christine
  Assignee(s): Shire Biochem Inc.
  This invention relates to a chewable lanthanum formulation comprising a pharmaceutically effective amount of a lanthanum compound; and at least one chewable pharmaceutically acceptable excipient. This invention also relates to a pharmaceutical formulation in a tablet or in a powder comprising a pharmaceutically effective amount of a lanthanum compound produced by a process which comprises the steps of: a) powder blending the lanthanum compound and at least one pharmaceutically acceptable excipient in a mixer to form a mixture; or b) powder blending the lanthanum compound and excipients, compressing the resulting combination into a slug material or roller compacting the resulting combination into a strand material, and milling the prepared material into a free flowing mixture; and c) compressing the resulting mixture into a tablet or filing up the resulting mixture in a appropriate container.
  
  Patent expiration dates:
  
  
  • August 26, 2024
    
    ✓ 
    Drug product
  
  

See also...

• Fosrenol Consumer Information (Drugs.com)
• Fosrenol Consumer Information (Wolters Kluwer)
• Fosrenol Consumer Information (Cerner Multum)
• Fosrenol Advanced Consumer Information (Micromedex)
• Fosrenol AHFS DI Monographs (ASHP)
• Lanthanum Carbonate Consumer Information (Wolters Kluwer)
• Lanthanum carbonate Consumer Information (Cerner Multum)
• Lanthanum carbonate Advanced Consumer Information (Micromedex)
• Lanthanum Carbonate AHFS DI Monographs (ASHP)